Navigation Links
Sinovac Reports Unaudited First Quarter 2011 Financial Results
Date:5/13/2011

or the same period of 2010. After deducting depreciation of land use rights, amortization of licenses, permits, the gross margin was 63.5% and 77.8% for the first quarter of 2011 and 2010, respectively. The gross profit margin was adversely affected by lower plant utilization in the first quarter of 2011 as reduced demand caused the Company to scale back production.

Selling, general and administrative expenses for the first quarter 2011 were $4.1 million, compared to $3.1 million in the same period of 2010. SG&A expenses as a percentage of first quarter 2011 sales were 87.75%, compared to 69.9% during the first quarter of the prior year.  The SG&A expenses as a percentage of revenue was in line with the increased sales in private pay market in the first quarter of 2011. However, the overall increase was resulted from an increase in selling expenses due to the adding of new sales personnel in the first quarter 2011.

Net research and development expenses for the first quarter 2011 were $2.1 million, compared to $1.1 million in the same period of 2010. The increased R&D expenses in the first quarter of 2011 were primarily related to the continued development of the pipeline vaccines, including the expenses on EV71 vaccine, which has entered the Phase I clinical trial, the trial production of the animal rabies vaccine and mumps vaccine, and other R&D projects.

Depreciation of property, plant and equipment and amortization of license and permits for the first quarter 2011 were $384,000, compared to $250,000 for the same period of last year.  The change compared to 2010 was primarily attributable to the Sinovac Dalian assets acquired in January 2010, with an additional 25% interest acquired in December 2010 for a majority interest of 55%, and Changping facility acquired in February 2010.

Total operating expenses for the first quarter of 2011 were $6.5 million, compared to $4.4 million in the comparative period in
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Sinovac Presents at Two Investor Conferences in May 2011
2. Sinovac Files Annual Report on Form 20-F
3. Sinovac Participates in UBS Greater China Healthcare Corporate Day
4. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
5. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
6. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
7. Sinovacs Stock Exchange Listing Moves to NASDAQ Global Select Market
8. Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine
9. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
10. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
11. Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (NYSE: DHR ) announced today that Henk ... and Amir Aghdaei and Henrik Roos have each been ... In his new role, Henk van Duijnhoven will ... Group and Sybron Dental Specialties.  Danaher,s Dental segment generated ...
... ALISO VIEJO, Calif., April 5, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the Future Leaders ... Location: Millennium Broadway Hotel & Conference Center, New York, ... Presentation time: 2:00pm ET A live ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2
(Date:4/22/2014)... patients diagnosed with non-small cell lung cancer are 70 ... percentage, these elderly patients are not well represented in ... made it difficult to reach evidence based clinical recommendations. ... Task Force and Lung Cancer Group along with the ... opinion on managing treatment for elderly patients with non-small ...
(Date:4/22/2014)... trauma, illness, alcohol or other drug abuse, these stressors ... that can go awry and activate conditions such as ... , Until now, it has been unclear how much ... brain. Past studies have shown that when an expectant ... she experiences some trauma or illness, her baby may ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Calgary,s Hotchkiss Brain Institute (HBI) uncovers ... as a means to restore connections after injury. Dr. ... molecule that directly regulates nerve cell growth in the ... prestigious journal Nature Communications , with lead authors ... made the surprising discovery that a protein called Retinoblastoma ...
Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... , ... ... ... ...
... ... ... ... ...
... sheds light on brain mechanism related to processing images , ... recognizing faces may be relieved to know that the problem ... could be in their genes, new research suggests. , The ... genes) and 125 non-identical, same-sex twins (who share 50 percent ...
... C. Bray of the University of Calgary was recently ... for Sports Medicine,s (AOSSM) $250,000 Ligament and Tendon Repair ... Ligament and Tendon Healing: Role of Neuropeptides." ... of Calgary, and Per Renstrom and Paul Ackermann, both ...
... mechanisms of transport have important applicationstransport of nutrients ... aeration of agricultural soils, performance of chemical reactors, ... and the design of clay membranes for retaining ... has important roles in biology, physics, and chemistry, ...
... ... depression and stress with amazing technology; free assessments offered in March. , ... Arlington, TX (Vocus) February 24, 2010 -- The ... trigger anxiety, loneliness, depression and even thoughts of suicide. At New Life Brain Center™, ...
Cached Medicine News:Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 2Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 3Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 4Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 5Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 6Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 7Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 8Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 9Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 10Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 11Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 12Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 13Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 14Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 15Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 16Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 17Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 18Health News:Soyfoods Aid Those With Lactose Intolerance 2Health News:Soyfoods Aid Those With Lactose Intolerance 3Health News:Soyfoods Aid Those With Lactose Intolerance 4Health News:Soyfoods Aid Those With Lactose Intolerance 5Health News:Trouble Recognizing Faces Could Be Genetic 2Health News:$250,000 grant awarded for groundbreaking ligament and tendon repair research 2Health News:Where does the fluid go? 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 3
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
... BD Vacutainer® SST™ Tubes ... a polymer gel for ... used for serum determinations ... provide an efficient means ...
MONOJECT Red/Yellow Mottled Stopper...
Medicine Products: